Posts tagged ‘Seattle Genetics’
Earlier this summer, the Food and Drug Administration (FDA) Oncology Drugs Advisory Committee (ODAC) announced a positive decision for Seattle Genetics’ Adcetris™ (brentuximab vedotin) in Hodgkin Lymphoma (HL) and Analplastic Large Cell Lymphoma (ALCL).
As Sally Church on Pharma Strategy Blog reported earlier this week, Seattle Genetics has just received fast track approval from the FDA for Adcetris™, a CD30-directed antibody drug-conjugate.
Using the company announced price of $13,500 per dose, Sally in her blog post analyzed the clinical trial data and treatment regimens to come up with a likely cost for a course of treatment in the range of $94,500 – $121,500.
Sally goes on to note that the “overall treatment cost will therefore be typically less than the $120K cost of treatment for BMS’s ipilimumab (Yervoy) in metastatic melanoma.”
The clinical data for Adcetris™ is impressive, and patients will most certainly benefit from the availability of this new treatment. Adcetris™ is the first antibody drug conjugate (ADC) technology to come to market.
You can read more about Sally’s analysis of the Adcetris™ price and other ADC products in the pipeline such as Roche’s T-DM1 on Pharma Strategy Blog.
In case you missed the 16th Congress of the European Hematology Association (EHA) that took place this past weekend in London, Sally Church has produced a video blog with her highlights from the meeting.
It’s tough doing ASCO and EHA back-to-back, but Sally is a seasoned road warrior. In the video we even see her working on the plane!
In her video blog, Sally talks about new data from the Congress in AML, systemic anaplastic large cell lymphoma (sALCL), and how pharma/biotech companies can do more with their drug packaging to help promote patient adherence to drug treatments.
Sally formerly worked at Novartis Oncology on imatinib (Gleevec®) in CML, so has expertise in this field. You can read more about EHA and hematology new products on Pharma Strategy Blog.
Published by Sally Church on Pharma Strategy Blog
Luke Timmerman on xconomy.com refers to Sally Church’s predictions published on Pharma Strategy Blog of what’s hot at ASH in 2010:
Published by Sally Church on Pharma Strategy Blog